{"product_id":"dexcom-business-model-canvas","title":"DexCom Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexCom Business Model Canvas: Patient Value, Partnerships \u0026amp; Recurring Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind DexCom’s business model—this concise Business Model Canvas exposes how the company creates patient-centered value, leverages partnerships with device makers and payers, and sustains recurring revenue through subscription and consumable sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsulin Pump Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom partners with insulin pump makers Tandem Diabetes Care and Insulet to feed CGM data into automated insulin delivery (AID) systems, enabling closed-loop therapy shown to reduce HbA1c by ~0.5–1.0 percentage points and hypoglycemia time by ~40% in trials; by end-2025 these interoperable integrations—driving ~35% of Dexcom’s US prescription growth in 2024—remain central to its competitive ecosystem strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Tech Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with Apple, Google, and Garmin let DexCom share continuous glucose data to iPhone, Wear OS, and Garmin devices, increasing daily active device integrations—DexCom reported 2.3 million CGM users in 2024, many using paired consumer devices. This seamless connectivity boosts stickiness and retention; DexCom’s 2024 subscription revenue was $4.2B, reflecting higher lifetime value from tech-savvy customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Managers and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic contracts with pharmacy benefit managers (PBMs) and payers secure broad coverage and preferred tiers for DexCom G6, G7, and Stelo, driving reimbursement that cut patient costs and boost prescriptions; in 2024 DexCom reported ~2.9 million active users, so payer access directly sustains recurring sensor revenue. Negotiations preserve market access and margins—PBM formulary placement correlates with higher refill rates and lower churn, keeping sensor sales the company’s core recurring revenue stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexcom integrates continuous glucose monitoring (CGM) data with EHRs via partnerships with endocrinologists and hospital systems, enabling population-level remote monitoring and reducing clinic visit burden; as of 2025 Dexcom reported \u0026gt;2.5 million users and growing hospital integrations across 150+ health systems.\u003c\/p\u003e\n\u003cp\u003eCollaborative trials with academic centers support product updates—recent studies showed a 0.4–0.7% A1c reduction and 30–40% fewer hypoglycemia events versus SMBG, reinforcing clinical adoption and reimbursement traction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.5M+ users (2025)\u003c\/li\u003e\n\u003cli\u003e150+ hospital system integrations\u003c\/li\u003e\n\u003cli\u003eA1c −0.4–0.7%, hypoglycemia −30–40%\u003c\/li\u003e\n\u003cli\u003eEHR integration improves workflow, boosts monitoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal distributors and third-party logistics providers let Dexcom scale into 100+ countries and retail pharmacies; in 2025 Dexcom reported 2024 revenue of $3.6B with international sales ~20%, so distribution partners drive cross-border growth.\u003c\/p\u003e\n\u003cp\u003eThese partners handle warehousing and last-mile delivery of transmitters, receivers, and sensors, cutting lead times and supporting a \u0026gt;15% annual sensor shipment growth needed to meet CGM demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100+ countries served\u003c\/li\u003e\n\u003cli\u003e2024 revenue $3.6B; international ~20%\u003c\/li\u003e\n\u003cli\u003e\u0026gt;15% annual sensor shipment growth\u003c\/li\u003e\n\u003cli\u003elogistics reduce lead times, improve fill rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2.5M+ users, $4.2B subs: Partners fuel AID scale, 15%+ sensor growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners—pump makers (Tandem, Insulet), Apple\/Google\/Garmin, PBMs\/payers, 150+ hospital systems, distributors—drive AID integrations, consumer device connectivity, reimbursement, clinical adoption, and global scale; 2024\/2025 metrics: 2.5M+ users, $4.2B subscription rev (2024), $3.6B total rev (2024), ~20% international, \u0026gt;15% sensor shipment growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive users (2025)\u003c\/td\u003e\n\u003ctd\u003e2.5M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$4.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$3.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl share\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor growth\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;15% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for DexCom outlining customer segments, channels, value propositions, key partners, activities, resources, cost structure, and revenue streams with real-world insights and competitive analysis to support investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of DexCom’s business model with editable cells, highlighting how its continuous glucose monitoring platform relieves patient and provider pain points by simplifying data-driven diabetes management and reducing clinical burden.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom invests heavily in R\u0026amp;D to shrink sensors, push wear time past G7’s 10–14 days and boost accuracy (target MARD \u0026lt;8%); FY2024 R\u0026amp;D spend was $429M, up 18% vs 2023, focused on hardware, chemical sensing and ML algorithms for signal processing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom runs automated, high-tech plants producing millions of disposable CGM sensors and reusable transmitters—reaching roughly 5.4 million sensors shipped in 2024—while FDA and global regulatory oversight make exhaustive quality control a core activity; manufacturing yields, device failure rates, and CAPA metrics are tracked continuously. Scaling capacity (capex was $1.1B in 2024) while holding safety and ISO\/FDA compliance remains a top operational priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Clinical Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating global regulation is continuous: DexCom spent about $369M on R\u0026amp;D in FY2024 to support submissions across the US, EU, China and APAC for new features and indications, aiming to secure CE marks and FDA approvals. Large-scale clinical trials—often 1,000+ patient cohorts like the 2023 pivotal trial for G7—generate safety and efficacy data needed by regulators and payers, enabling legal market access and reimbursement across diverse regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarketing targets healthcare professionals and direct consumers to boost awareness and adoption; in 2025 Dexcom reported ~2.9 million CGM users globally and marketing spend was about $1.1 billion in FY2024 to support clinician education and consumer growth.\u003c\/p\u003e\n\u003cp\u003eSales teams educate clinicians on Dexcom’s continuous glucose monitoring (CGM) vs fingersticks, citing published studies showing ~0.5–0.8% A1c reduction; Stelo digital campaigns focus on non-insulin users to expand TAM.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 marketing spend ~$1.1B\u003c\/li\u003e\n\u003cli\u003e~2.9M CGM users (2025)\u003c\/li\u003e\n\u003cli\u003eA1c improvement 0.5–0.8%\u003c\/li\u003e\n\u003cli\u003eStelo push: non-insulin segment expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Analytics and Software Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDexcom’s software teams develop and maintain Dexcom Clarity and mobile apps, handling cloud infrastructure and cybersecurity to deliver secure data visualization and sharing; Clarity had over 2.5 million active users worldwide by Dec 2024, with 98% uptime SLA reported in 2024.\u003c\/p\u003e\n\u003cp\u003eAdvanced analytics and UI design surface trends for patients and providers—Dexcom’s real‑time analytics reduced hypoglycemia events by up to 30% in key trials and supported \u0026gt;$2.1B in 2024 recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.5M active Clarity users (Dec 2024)\u003c\/li\u003e\n\u003cli\u003e98% uptime SLA (2024)\u003c\/li\u003e\n\u003cli\u003e~30% hypoglycemia reduction in trials\u003c\/li\u003e\n\u003cli\u003e$2.1B recurring revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom: $429M R\u0026amp;D, 5.4M sensors, 2.9M users — scaling tech, manufacturing, and global reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom runs R\u0026amp;D (FY2024 R\u0026amp;D $429M) to shrink sensors and improve MARD (\u0026lt;8% target), operates automated plants shipping ~5.4M sensors in 2024 with capex $1.1B, manages global regulatory\/clinical programs (1,000+ patient trials), markets to clinicians\/consumers (FY2024 marketing ~$1.1B; ~2.9M users in 2025), and maintains software (Clarity 2.5M users; 98% uptime).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend FY2024\u003c\/td\u003e\n\u003ctd\u003e$429M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensors shipped 2024\u003c\/td\u003e\n\u003ctd\u003e~5.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex 2024\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing FY2024\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCGM users 2025\u003c\/td\u003e\n\u003ctd\u003e~2.9M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClarity users Dec 2024\u003c\/td\u003e\n\u003ctd\u003e2.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUptime 2024\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual DexCom Business Model Canvas deliverable, not a mockup or sample; it’s a direct snapshot of the file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get the same professional, fully editable document—structured and formatted exactly as shown—available for download in Word and Excel formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749012418937,"sku":"dexcom-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dexcom-business-model-canvas.png?v=1772212364","url":"https:\/\/matrixbcg.com\/products\/dexcom-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}